SEVERE ALOPECIA AREATA
Clinical trials for SEVERE ALOPECIA AREATA explained in plain language.
Never miss a new study
Get alerted when new SEVERE ALOPECIA AREATA trials appear
Sign up with your email to follow new studies for SEVERE ALOPECIA AREATA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug litfulo monitored in 3,000 patients for hair loss control
Disease control Recruiting nowThis study follows 3,000 people in Korea with severe alopecia areata who are starting Litfulo. Researchers will track side effects and how well the drug regrows hair over 48 weeks. The goal is to confirm safety and effectiveness in real-world use.
Matched conditions: SEVERE ALOPECIA AREATA
Sponsor: Pfizer • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for severe hair loss: daily pill tested in Long-Term study
Disease control Recruiting nowThis study looks at the long-term safety and effects of a daily pill called ritlecitinib for people with severe alopecia areata, a condition causing major hair loss. Participants who completed earlier studies can join and will take the medicine for up to 3 years. The goal is to s…
Matched conditions: SEVERE ALOPECIA AREATA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Hair loss hope: daily pill trial for kids with severe alopecia
Disease control Recruiting nowThis study tests a daily pill called ritlecitinib for children aged 6 to 12 with severe alopecia areata, a condition causing significant hair loss. About 225 kids will receive either a high dose, low dose, or placebo for 6 months. The goal is to see if the medicine can safely reg…
Matched conditions: SEVERE ALOPECIA AREATA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug IBI3013 enters human testing for skin and hair loss conditions
Disease control Recruiting nowThis early-stage study tests a new drug called IBI3013. First, healthy adults receive a single dose to check safety and how the body processes it. Then, people with active vitiligo (white patches on skin) or severe alopecia areata (patchy hair loss) receive multiple doses. The go…
Matched conditions: SEVERE ALOPECIA AREATA
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC